Location of Repository

Activation of a novel natriuretic endocrine system in humans with heart failure

By Hafid Narayan, Noor Mohammed, Paulene A. Quinn, Iain B. Squire, Joan E. Davies and Leong L. Ng

Abstract

Proguanylin and prouroguanylin are the inactive precursors of guanylin and uroguanylin, natriuretic peptides involved in the regulation of sodium balance. Urinary uroguanylin levels have been found previously to be elevated in patients with HF (heart failure). The aim of the present study was to investigate whether plasma proguanylin and prouroguanylin levels are increased in patients with HF and to evaluate their relationship with cardiac and renal function. In this prospective observational study, we recruited 243 patients with HF (151 men) and 72 healthy controls. In patients with HF, plasma levels of proguanylin [median, 7.2 (range, 0.9-79.0) microg/l] and prouroguanylin [8.3 (1.7-53.0 microg/l)] were both significantly (P<0.0005) higher compared with levels in healthy controls [5.5 (0.4-22.3 microg/l) for proguanylin and 6.3 (2.5-16.9) microg/l for prouroguanylin]. In patients with HF, increased age, a history of hypertension, diabetes and atrial fibrillation, use of diuretics, a higher NYHA (New York Heart Association) class and a lower eGFR (estimated glomerular filtration rate) were significant univariate predictors of proguanylin and prouroguanylin levels. In multivariate analysis, a history of hypertension and low eGFR both had strong independent associations with proguanylin and prouroguanylin levels. Proguanylin and prouroguanylin varied significantly between NYHA class with a trend of increasing plasma concentrations with worsening severity of symptoms. In conclusion, plasma proguanylin and prouroguanylin are elevated in patients with HF. Elevated plasma proguanylin and prouroguanylin levels are associated with hypertension, renal impairment and increasing severity of HF. This novel endocrine system may contribute to the pathophysiology of HF.N.M. is supported by the Nuffield Hospital Leicester, and H.N. is supported by a British Heart Foundation clinical research training fellowship [grant number FS/09/040]. We are also grateful for the support of the Leicester Cardiovascular Biomedical Research Unit through the National Institute of Health Research

Topics: heart failure, hypertension, natriuretic peptide, proguanylin, prouroguanylin, sodium balance
Publisher: Portland Press
Year: 2009
DOI identifier: 10.1042/CS20090338
OAI identifier: oai:lra.le.ac.uk:2381/7844
Journal:

Suggested articles

Preview

Citations

  1. (1975). A comparison of natriuresis after oral and intravenous sodium loading in sodium-depleted man: evidence for a gastrointestinal or portal monitor of sodium intake. doi
  2. (2003). A novel role for uroguanylin in the regulation of sodium balance. doi
  3. (2007). Altered intestinal function in patients with chronic heart failure. doi
  4. and others doi
  5. (1994). Characterization of human uroguanylin: a member of the guanylin peptide family.
  6. (2008). Circulating prouroguanylin is processed to its active natriuretic form exclusively within the renal tubules. doi
  7. (1996). Cloning and characterization of a cDNA encoding a precursor for human uroguanylin. doi
  8. (2006). Drawbacks and prognostic value of formulas estimating renal function in patients with chronic heart failure and systolic dysfunction. Circulation doi
  9. (2009). Evaluation of novel biomarkers for the diagnosis of acute destabilized heart failure in shortness-of-breath patients. doi
  10. (2004). Guanylin and uroguanylin induce natriuresis in mice lacking guanylyl cyclase-C receptor. doi
  11. (1992). Guanylin: an endogenous activator of intestinal guanylate cyclase. doi
  12. (2001). High salt intake increases uroguanylin expression in mouse kidney. doi
  13. (1992). Human guanylin: cDNA isolation, structure, and activity. doi
  14. (2000). Increased urinary excretion of uroguanylin in patients with congestive heart failure.
  15. (2006). Mechanisms of action of uroguanylin and guanylin and their role in salt handling. doi
  16. (1992). Precursor structure, expression, and tissue distribution of human guanylin. doi
  17. (2002). Site-specific effects of dietary salt intake on guanylin and uroguanylin mRNA expression in rat intestine. doi
  18. (2004). Studies on intragastric PCO2 at rest and during exercise as a marker of intestinal perfusion in patients with chronic heart failure. doi
  19. (2008). Uroguanylin, an intestinal natriuretic peptide, is delivered to the kidney as an unprocessed propeptide. doi

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.